Sansum Clinic
Decrease (-) Restore Default Increase (+) font size


FacebookIcon.jpg  TwitterIcon.jpg  YouTubeIcon.jpg  InstagramIcon.jpg

 Follow us for healthy tips & info!


The objective of this Asthma study is to evaluate the effect of the drug Omalizumab on certain allergic markers that trigger asthma. This will be measured by the Asthma Control Test (ACT) scores at 24 weeks of treatment.

This study is for patients with inadequately controlled persistent allergic asthma.

Who is Eligible to Participate?

  • Male or female 12 years of age or older 
  • History of positive skin prick test or RAST test within the last 12 months to at least one perennial aeroallergen (i.e. cat dander, dog dander, dust mite, cockroach)
  • Diagnosis of asthma for at least 12 months prior to screening visit date, or symptoms compatible with asthma for at least 12 months if diagnosis made within 12 months of screening visit
  • Prescribed and using at least medium dose inhaled corticosteroids such as fluticasone DPI> 300mcg / day or equivalent
  • Bodyweight not more than 150kg
  • Currently a non-smoker for at least 1 year prior to Visit 1, with a smoking history of no more than 10 pack-years

What is Involved?

The trial consists of two periods:

  • Screening period consists of 2 weeks to establish patient's eligibility for the trial
  • Double-blind treatment period is randomized, double blind, placebo-controlled for 24 weeks

Total duration of patient's participation is 26 weeks.


Study Details

             Principal Investigator
Myron L. Liebhaber, MD

             Study Coordinator
Mary Lou Schroeder, RN 
             Trial Status
             Study Length
26 Weeks 

Related Links
© 2017 Sansum Clinic